Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?

Literature DB >> 24801017

Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?

Matteo Molica¹, Alessandra Serrao, Roberta Saracino, Irene Zacheo, Christof Stingone, Giuliana Alimena, Massimo Breccia.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
INCB018424
Pyrazoles

Year: 2014 PMID： 24801017 DOI： 10.1007/s00277-014-2096-y

Source DB: PubMed Journal: Ann Hematol ISSN： 0939-5555 Impact factor: 3.673

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Fatal ruxolitinib-related JC virus meningitis.

Authors: Begoña Ballesta; Héctor González; Vicente Martín; Juan J Ballesta
Journal: J Neurovirol Date: 2017-08-08 Impact factor: 2.643

Review 2. Ruxolitinib dose management as a key to long-term treatment success.

Authors: Ruben A Mesa; Rami S Komrokji; Srdan Verstovsek
Journal: Int J Hematol Date: 2016-08-27 Impact factor: 2.490

Review 3. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors: Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal: Future Oncol Date: 2015 Impact factor: 3.404

Review 4. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.

Authors: Abdallah Abou Zahr; Mohamed E Salama; Nicole Carreau; Douglas Tremblay; Srdan Verstovsek; Ruben Mesa; Ronald Hoffman; John Mascarenhas
Journal: Haematologica Date: 2016-06 Impact factor: 9.941

Review 5. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Authors: A Yacoub; O Odenike; S Verstovsek
Journal: Curr Hematol Malig Rep Date: 2014-12 Impact factor: 3.952

Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?

1. Fatal ruxolitinib-related JC virus meningitis.

Review 2. Ruxolitinib dose management as a key to long-term treatment success.

Review 3. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Review 4. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.

Review 5. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Review 6. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.

Review 7. Treatment of Myelofibrosis: Old and New Strategies.

Review 8. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.

Review 9. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

Review 10. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.